Vraylar vs Latuda
A side-by-side look at two mental health medications advertised on TV. Informational only — not medical advice.
| US Vraylar | US Latuda | |
|---|---|---|
| Generic name | cariprazine | lurasidone |
| Drug class | Atypical Antipsychotic | Atypical Antipsychotic |
| Treats | Bipolar disorder, schizophrenia, depression (add-on) | Schizophrenia, bipolar depression |
| Category | Mental Health | Mental Health |
| Manufacturer | AbbVie | Sunovion (Sumitomo) |
| Year approved | 2015 | 2010 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $200M | $85M |
| Common side effects | Movement disorders, Drowsiness, Restlessness, Weight changes | Sleepiness, Restlessness, Nausea, Movement problems |
Frequently asked questions
Is Vraylar or Latuda better?
Neither is universally "better." Vraylar (cariprazine) and Latuda (lurasidone) are both used for mental health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vraylar and Latuda?
Vraylar is a Atypical Antipsychotic made by AbbVie, while Latuda is a Atypical Antipsychotic made by Sunovion (Sumitomo). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vraylar has the larger estimated TV advertising budget of the two.